Phase II single-arm, single-institution trial of neoadjuvant gemcitabine and oxaliplatin treatment (NT) in patients (pts) with resectable pancreas adenocarcinoma (PC)

被引：0
|
作者：
O'Reilly, E. M.
Jarnagin, W. R.
Brennan, M. F.
Winston, C.
Tang, L. H.
Capanu, M.
Schattner, M.
Chen, L. Y.
DeMatteo, R. P.
DiMaio, C. J.
D'Angelica, M. I.
Kurtz, R. C.
Klimstra, D. S.
Lowery, M. A.
Coit, D. G.
Reidy, D. L.
Allen, P. J.
机构：
[1] Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA
[2] Mem Sloan Kettering Canc Ctr, Dept Pathol, New York, NY 10021 USA
[3] Mem Sloan Kettering Canc Ctr, Dept Surg, New York, NY 10021 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2011年 / 29卷 / 15期
关键词：
D O I：
10.1200/jco.2011.29.15_suppl.4065
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
4065
引用
收藏
页数：1
相关论文
共 50 条
  • [1] A Single-Arm, Nonrandomized Phase II Trial of Neoadjuvant Gemcitabine and Oxaliplatin in Patients With Resectable Pancreas Adenocarcinoma
    O'Reilly, Eileen M.
    Perelshteyn, Anna
    Jarnagin, William R.
    Schattner, Mark
    Gerdes, Hans
    Capanu, Marinela
    Tang, Laura H.
    LaValle, Joseph
    Winston, Corinne
    DeMatteo, Ronald P.
    D'Angelica, Michael
    Kurtz, Robert C.
    Abou-Alfa, Ghassan K.
    Klimstra, David S.
    Lowery, Maeve A.
    Brennan, Murray F.
    Coit, Daniel G.
    Reidy, Diane L.
    Kingham, T. Peter
    Allen, Peter J.
    ANNALS OF SURGERY, 2014, 260 (01) : 142 - 148
  • [2] A single-arm, phase II trial of neoadjuvant gemcitabine and S1 in patients with resectable and borderline resectable pancreatic adenocarcinoma: PREP-01 study
    Fuyuhiko Motoi
    Sohei Satoi
    Goro Honda
    Keita Wada
    Hiroyuki Shinchi
    Ippei Matsumoto
    Masayuki Sho
    Akihiko Tsuchida
    Michiaki Unno
    Journal of Gastroenterology, 2019, 54 : 194 - 203
  • [3] A single-arm, phase II trial of neoadjuvant gemcitabine and S1 in patients with resectable and borderline resectable pancreatic adenocarcinoma: PREP-01 study
    Motoi, Fuyuhiko
    Satoi, Sohei
    Honda, Goro
    Wada, Keita
    Shinchi, Hiroyuki
    Matsumoto, Ippei
    Sho, Masayuki
    Tsuchida, Akihiko
    Unno, Michiaki
    Kurata, M.
    Yanagimoto, H.
    Toyama, H.
    Nagakawa, Y.
    Maemura, K.
    Mataki, Y.
    Akahori, T.
    Kinoshita, S.
    Terashima, H.
    Horiguchi, A.
    Ohtsuka, Y.
    Nanashima, A.
    Kanemitsu, K.
    Ohigashi, H.
    Tani, M.
    Takahara, T.
    Shiomi, H.
    Endo, I.
    Suzuki, H.
    Rikiyama, T.
    Ikoma, H.
    Yasunaga, M.
    Nakamura, K.
    Egawa, S.
    Katayose, Y.
    Nakagawa, K.
    Okada, K.
    Ottomo, S.
    JOURNAL OF GASTROENTEROLOGY, 2019, 54 (02) : 194 - 203
  • [4] Neoadjuvant Chemoradiotherapy Combined with Atezolizumab for Resectable Esophageal Adenocarcinoma: A Single-arm Phase II Feasibility Trial (PERFECT)
    van den Ende, Tom
    de Clercq, Nicolien C.
    Henegouwen, Mark I. van Berge
    Gisbertz, Suzanne S.
    Geijsen, E. D.
    Verhoeven, R. H. A.
    Meijer, Sybren L.
    Schokker, Sandor
    Dings, M. P. G.
    Bergman, Jacques J. G. H. M.
    Mohammad, Nadia Haj
    Ruurda, Jelle P.
    van Hillegersberg, Richard
    Mook, Stella
    Nieuwdorp, Max
    de Gruijl, Tanja D.
    Soeratram, Tanya T. D.
    Ylstra, Bauke
    van Grieken, Nicole C. T.
    Bijlsma, Maarten F.
    Hulshof, Maarten C. C. M.
    van Laarhoven, H. W. M.
    CLINICAL CANCER RESEARCH, 2021, 27 (12) : 3351 - 3359
  • [5] Neoadjuvant toripalimab plus axitinib in patients (pts) with resectable mucosal melanoma (MuM): Updated findings of a single-arm, phase II trial
    Cui, C-L.
    Li, Z.
    Wu, N.
    Li, M.
    Chen, X.
    Zheng, H.
    Gao, M.
    Wang, D.
    Lian, B.
    Wang, X.
    Tian, H.
    Si, L.
    Chi, Z.
    Sheng, X.
    Lai, Y.
    Sun, T.
    Zhang, Q.
    Kong, Y.
    Guo, J.
    ANNALS OF ONCOLOGY, 2022, 33 (07) : S908 - S908
  • [6] A multi-institutional, single-arm, phase II trial of neoadjuvant modified-FOLFIRINOX for resectable pancreatic ductal adenocarcinoma
    Lee, Choong-kun
    Hwang, Ho Kyoung
    Jeung, Hei-Cheul
    Chon, Hongjae
    Park, Hyung Soon
    Kim, Min Hwan
    Park, Mi-Suk
    Kang, Chang Moo
    Choi, Hye Jin
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (04)
  • [7] A multi-institutional, single-arm, phase II trial of neoadjuvant modified-FOLFIRINOX for resectable pancreatic ductal adenocarcinoma.
    Lee, Choong-kun
    Hwang, Ho Kyoung
    Jeung, Hei-Cheul
    Chon, Hongjae
    Park, Hyung Soon
    Kim, Min Hwan
    Kim, Sung Hyun
    Park, Mi-Suk
    Kang, Chang Moo
    Choi, Hye Jin
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 : 715 - 715
  • [8] Neoadjuvant Atezolizumab With Gemcitabine and Cisplatin in Patients With Muscle-Invasive Bladder Cancer: A Multicenter, Single-Arm, Phase II Trial
    Funt, Samuel A.
    Lattanzi, Michael
    Whiting, Karissa
    Al-Ahmadie, Hikmat
    Quinlan, Colleen
    Teo, Min Yuen
    Lee, Chung-Han
    Aggen, David
    Zimmerman, Danielle
    McHugh, Deaglan
    Apollo, Arlyn
    Durdin, Trey D.
    Truong, Hong
    Kamradt, Jeffrey
    Khalil, Maged
    Lash, Bradley
    Ostrovnaya, Irina
    McCoy, Asia S.
    Hettich, Grace
    Regazzi, Ashley
    Jihad, Marwah
    Ratna, Neha
    Boswell, Abigail
    Francese, Kaitlyn
    Yang, Yuanquan
    Folefac, Edmund
    Herr, Harry W.
    Donat, S. Machele
    Pietzak, Eugene
    Cha, Eugene K.
    Donahue, Timothy F.
    Goh, Alvin C.
    Huang, William C.
    Bajorin, Dean F.
    Iyer, Gopa
    Bochner, Bernard H.
    Balar, Arjun V.
    Mortazavi, Amir
    Rosenberg, Jonathan E.
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (12) : 1312 - +
  • [9] A single-arm, phase II feasibility study of neoadjuvant docetaxel, oxaliplatin, and S-1 (DOS) chemotherapy in potentially resectable gastric or gastroesophageal junction adenocarcinoma
    Ryu, M.
    Choi, Y.
    Kim, B.
    Park, Y.
    Kim, H.
    Jung, H.
    Lee, G.
    Kim, K.
    Yook, J.
    Kang, Y.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (04)
  • [10] Efficacy and toxicity results of neoadjuvant gemcitabine-based combined chemoradiotherapy in patients with borderline resectable pancreatic adenocarcinoma: A single-institution experience
    Diaz Beveridge, R.
    Garcia-Mora, C.
    Moya, A.
    Bruixola, G.
    Aparicio, J.
    Reche, E.
    Segura, A.
    Caballero, J.
    Gimenez, A.
    Bennis, H.
    EUROPEAN JOURNAL OF CANCER, 2013, 49 : S591 - S591
12345